EUVIMEDEUVIMED entdecken
Vergleichsstudie

[⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study

Shengyan Liu, Xin Zhang, Ruochen Li, Ziren Kong, Xi-Yang Cui, Zhu Li, Cong Shi, Dongxiao Bian, Yihan Zhao, Qijun Li, Yijin Pan, Zhaohui Zhu und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8497-8507

DOI: 10.1007/s00259-026-08150-4 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 05.09.2026. Verfasst von Shengyan Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Acade…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Thyroid Neoplasms, Gallium Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National High-Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Incorporating a sulfur (VI)-fluoride exchange (SuFEx) chemistry-based linker, FAPI-based covalent targeted radioligand (CTR) showed better tumor binding affinity and longer retention time than FAPI-04 in animal studies. This study for the first time compared the lesion detection efficacy of [⁶⁸Ga]Ga-CTR-FAPI PET/CT and [⁶⁸Ga]Ga-FAPI-04 PET/CT in a radioiodine-refractory differentiated thyroid cancer clinical cohort. METHODS: A single-center prospective comparative study was conducted, enrolling 40 RAIR-DTC patients with distant metastases. All patients underwent sequential [⁶⁸Ga]Ga-FAPI-04 PET/CT and [⁶⁸Ga]Ga-CTR-FAPI PET/CT examinations at a 24-48 h interval. Two experienced nuclear medicine physicians performed blinded visual analysis of the images to assess lesion detection status. Semi-quantitative analysis included the measurement of maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) of lesions in different anatomical regions. The reference standard for lesion confirmation was a combination of conventional imaging, histopathological results (when feasible), and long-term clinico-radiological follow-up. The detection performances of the two imaging modalities were compared at the patient and lesion levels. RESULTS: Of the 40 enrolled patients, 37 had detectable metastatic lesions on both imaging modalities. Two patients had lesions exclusively detected by [⁶⁸Ga]Ga-CTR-FAPI PET/CT. [⁶⁸Ga]Ga-CTR-FAPI PET/CT achieved superior visual detection performance in 17.5% (7/40) of patients (p = 0.016) concerning lesion distribution areas. In total, 769 metastatic lesions were identified by the two tracers, with [⁶⁸Ga]Ga-CTR-FAPI PET/CT detecting 99.2% (763/769) and [⁶⁸Ga]Ga-FAPI-04 PET/CT detecting 62.4% (480/769) of lesions (p < 0.001). [⁶⁸Ga]Ga-CTR-FAPI PET/CT significantly improved detection rates in lung (99.4% vs. 37.5%, p < 0.001), pleural/peritoneal (99.0% vs. 76.4%, p < 0.001), lymph node (99.0% vs. 81.7%, p < 0.001) and bone (100% vs. 82.9%, p = 0.031) metastases. Semi-quantitative analysis showed that [⁶⁸Ga]Ga-CTR-FAPI PET/CT had significantly higher median SUVmax in lung (5.1 vs. 3.8, p < 0.001) and bone (8.3 vs. 3.4, p = 0.013) metastases, and significantly higher median TBR in local recurrence (11.2 vs. 8.6, p = 0.045) and lymph node metastases (6.0 vs. 5.1, p = 0.026) compared with [⁶⁸Ga]Ga-FAPI-04 PET/CT. Furthermore, [⁶⁸Ga]Ga-CTR-FAPI PET/CT exhibited additional cerebral and hepatic metastatic lesions as well as higher tracer uptake in shared lesions located at brain (n = 1), liver(n = 2) and kidney (n = 1), while the only mediastinal soft tissue metastasis showed an SUVmax slightly higher in [⁶⁸Ga]Ga-FAPI-04 PET/CT. CONCLUSION: [⁶⁸Ga]Ga-CTR-FAPI PET/CT exhibits superior lesion detection rate, higher tracer uptake and better tumor-to-background contrast compared with [⁶⁸Ga]Ga-FAPI-04 PET/CT in RAIR-DTC patients, thus enhances the comprehensive assessment of patients' tumor burden. These findings stimulate further research on the application of CTR-FAPI as a novel and promising theranostic agent. TRIAL REGISTRATION: ChiCTR ChiCTR2400091757. Registered 2 November 2024.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyThyroid NeoplasmsGallium RadioisotopesHumansFemaleMaleMiddle AgedProspective StudiesAdultIodine RadioisotopesAgedFibroblast Activation Protein AlphaRadiopharmaceuticalsQuinolines

Stichwörter der Autor:innen

Covalent targeted radioligandFibroblast activation protein inhibitorRadioiodine-refractory differentiated thyroid cancer

Substanzen

Iodine RadioisotopesGallium RadioisotopesFibroblast Activation Protein Alpha68Ga-FAPIRadiopharmaceuticalsQuinolines

Autor:innen und Institutionen

  • Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuy…
  • Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear medicine, Beijing, China.
  • Department of Head and Neck Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Changping Laboratory, Beijing, China.
  • Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • National High-Level Hospital Clinical Research Funding

Zitieren

APA

Liu, S., Zhang, X., Li, R., Kong, Z., Cui, X. Y., Li, Z., Shi, C., Bian, D., Zhao, Y., Li, Q., Pan, Y., Zhu, Z., Liu, Z., Liu, S., & Lin, Y. (2026). [⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8497-8507. https://doi.org/10.1007/s00259-026-08150-4

Vancouver

Liu S, Zhang X, Li R, Kong Z, Cui XY, Li Z, et al. [⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8497-8507. doi:10.1007/s00259-026-08150-4

BibTeX
@article{Liu2026,
  author = {Liu, Shengyan and Zhang, Xin and Li, Ruochen and Kong, Ziren and Cui, Xi-Yang and Li, Zhu and Shi, Cong and Bian, Dongxiao and Zhao, Yihan and Li, Qijun and Pan, Yijin and Zhu, Zhaohui and Liu, Zhibo and Liu, Shaoyan and Lin, Yansong},
  title = {[⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8497--8507},
  doi = {10.1007/s00259-026-08150-4}
}
Kostenlos starten →